Emmes Group Appointed Rama Kondru as New CEO
The board of directors selected Rama Kondru to lead the company following his tenure as CEO of Veridix.
Updated on Sept. 21, 2026 in People
Live Poll
Do you believe new executive leadership usually leads to better outcomes for a company's stakeholders?
The Emmes Group Board of Directors has appointed Rama Kondru as the company's new CEO. Kondru brings two and a half decades of professional experience to the organization as it looks to evolve its clinical trial operations.
Why it matters
The board selected Kondru for his extensive background in healthcare technology and data science. His appointment aims to help the firm leverage artificial intelligence to modernize how it designs and conducts clinical trials.
Rama Kondru holds 25 years of cross-industry experience in pharmaceuticals, data science, and healthcare technology. This tenure includes prior leadership roles at Janssen Americas, Medidata Solutions, and Veridix.
The players
Rama Kondru
He is the newly appointed CEO of The Emmes Group who previously served as the CEO of Veridix and Co-CEO of Medidata Solutions.
The Emmes Group
This is a clinical research organization that focuses on combining technology and data science to improve clinical trial design.
The details
The Emmes Group aims to combine its clinical expertise with new technological capabilities under Kondru's leadership. The organization plans to prioritize the integration of artificial intelligence to improve the efficiency of trial design and management.
Timeline
Rama Kondru joined the Emmes Group in 2024.
The Emmes Group announced the appointment of Kondru as CEO on September 21, 2026.
Market Landscape
The appointment of a technology-focused CEO reflects the broader industry trend of integrating AI into clinical trial management. This move positions The Emmes Group to compete more aggressively against firms modernizing their data science and drug development pipelines.
Clients and partners of the firm may see shifts in how clinical trials are designed as the company adopts new AI-driven platforms. The change signals a transition toward more data-heavy service models for healthcare technology users.
The takeaway
The move underscores the growing necessity for leaders who bridge the gap between traditional clinical research and emerging data technologies. Companies that fail to integrate these high-tech systems risk falling behind in the global race for faster drug development cycles.
Further reading
Learn more about executive leadership changes in the industry at People.
Source note: This article includes information reported by PMLive.
Live Poll
Do you believe new executive leadership usually leads to better outcomes for a company's stakeholders?
